Parnassus Investments LLC Sells 15,239 Shares of Repligen Co. (NASDAQ:RGEN)

Parnassus Investments LLC reduced its stake in shares of Repligen Co. (NASDAQ:RGEN) by 4.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 366,232 shares of the biotechnology company’s stock after selling 15,239 shares during the quarter. Parnassus Investments LLC owned 0.65% of Repligen worth $52,715,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of RGEN. Atria Investments Inc grew its position in Repligen by 67.9% during the 3rd quarter. Atria Investments Inc now owns 3,202 shares of the biotechnology company’s stock worth $477,000 after acquiring an additional 1,295 shares during the last quarter. Crossmark Global Holdings Inc. boosted its stake in shares of Repligen by 12.0% during the third quarter. Crossmark Global Holdings Inc. now owns 4,068 shares of the biotechnology company’s stock valued at $606,000 after purchasing an additional 436 shares during the period. State of New Jersey Common Pension Fund D grew its holdings in shares of Repligen by 2.0% in the third quarter. State of New Jersey Common Pension Fund D now owns 19,700 shares of the biotechnology company’s stock worth $2,932,000 after purchasing an additional 382 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of Repligen in the third quarter worth $306,000. Finally, Venturi Wealth Management LLC increased its stake in shares of Repligen by 28.1% in the third quarter. Venturi Wealth Management LLC now owns 1,369 shares of the biotechnology company’s stock worth $204,000 after buying an additional 300 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

RGEN has been the topic of a number of recent analyst reports. Wolfe Research began coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Canaccord Genuity Group raised their target price on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. Canaccord Genuity Group started coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $181.00.

Repligen Price Performance

Shares of RGEN stock opened at $142.44 on Friday. The business’s fifty day moving average is $157.17 and its 200 day moving average is $148.45. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock has a market cap of $7.98 billion, a price-to-earnings ratio of -279.29, a PEG ratio of 4.54 and a beta of 0.95. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $200.23.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Research analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.